Loading
A phase 1 trial of JY232 run by Shenzhen Genocury Biotech Co., Ltd., now recruiting.
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT07336823 by Shenzhen Genocury Biotech Co., Ltd., with 9 participants planned, started 2026-01-20, primary completion expected 2028-12-31. Conditions recorded: Multiple Myeloma. Interventions recorded: JY232 Injection.
Shares Genocury Biotech and the tag pipeline.
Shares Genocury Biotech and the tag pipeline.
Shares Genocury Biotech and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/